Literature DB >> 11739436

Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry.

H Vierhapper1, P Nowotny, H Maier, W Waldhäusl.   

Abstract

Production rates of dihydrotestosterone (DHT) were determined in healthy men (n = 8), in healthy women during the follicular phase of their menstrual cycle (n = 7), and in young men with male pattern baldness (n = 8) using the stable isotope dilution technique and mass spectrometry. [2,3,4-(13)C]DHT was infused for 10 h at doses of 15 microg/h (men) and 2 microg/h (women), and blood samples were obtained at 20-min intervals during the last 4 h of the observation period. Production rates estimated between April and June were 2.9 +/- 1.1 microg/h (women) and 17.8 +/- 6.2 microg/h (men). In men production rates of DHT were similar (16.2 +/- 7.7 microg/h) when the investigation was repeated between October and December. Mean production rates of DHT in young men with male pattern baldness (60 +/- 50 microg/h) were higher than those in healthy men (P < 0.005). Although this group included two individuals with normal production rates of DHT, the production rate of DHT was markedly elevated (range, 32.0-161.0 microg/h) in the remaining patients. Stable isotope-labeled infusions of DHT are suitable for clinical use in a routine setting to obtain analytically correct estimates of DHT production in vivo. In the majority of men with male pattern baldness endogenous production of DHT is markedly increased, providing a rationale for therapeutic 5 alpha-reductase inhibition in this disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739436     DOI: 10.1210/jcem.86.12.8078

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.

Authors:  Carla Di Loreto; Francesco La Marra; Giorgio Mazzon; Emanuele Belgrano; Carlo Trombetta; Sabina Cauci
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

2.  Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia.

Authors:  Izabela Urysiak-Czubatka; Małgorzata L Kmieć; Grażyna Broniarczyk-Dyła
Journal:  Postepy Dermatol Alergol       Date:  2014-09-08       Impact factor: 1.837

3.  Elevated Oxytocin Receptor Blood Concentrations Predict Higher Risk for, More, and Earlier 24-Month Hospital Readmissions after In-Patient Detoxification in Males with Alcohol Use Disorder.

Authors:  Christiane Mühle; Massimiliano Mazza; Christian Weinland; Claudia von Zimmermann; Patrick Bach; Falk Kiefer; Valery Grinevich; Iulia Zoicas; Johannes Kornhuber; Bernd Lenz
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

4.  Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men.

Authors:  Yingchun Zhang; Jingjing Xu; Jing Jing; Xianjie Wu; Zhongfa Lv
Journal:  Med Sci Monit       Date:  2018-10-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.